PDZ Binding Kinase (PBK) Immunoexpression in Invasive Pituitary Adenomas: An Exploratory Study

Abstract

Background

Although pituitary adenomas (PAs) are believed to be benign neoplasms, invasion and recurrence are known in these tumors. Invasive PAs may not be amenable to complete excision and hence pose a challenge in the surgical management. Few previous studies have identified matrix metalloproteinase and vascular endothelial growth factor as possible contributors to invasion in PA, with no conclusive evidence. We studied the expression of a novel biomarker, PDZ-binding kinase (PBK) in invasive PA. PBK has earlier been shown to contribute to aggressiveness in glioblastoma, by our group.

Materials and Methods

A total of 23 invasive pituitary PAs were included. As controls, normal adenohypophysis and 10 noninvasive PAs were also studied. In all the cases, clinical, radiological, histopathological, and immunohistochemical profiles were analyzed. Invasion was defined based on radiological findings. Further, immunohistochemistry with PBK antibody was carried out and analyzed.

Results

Mean age in invasive PA was 47.6 years, in noninvasive PA was 48.6 years. The most common site of invasion was the cavernous sinus-unilateral (21.7%), and bilateral in 65.2%. The common presentation was vision involvement in both. The mean volume in the invasive group was 31.95 cc, and in the noninvasive group, it was 9.79 cc. The common surgical approach was the endoscopic transnasal approach in both groups. The majority of invasive (47.8%) and noninvasive (70%) PAs were gonadotroph adenomas. PBK immunopositivity was noted in 20/23 (87%) invasive PAs, while it was not observed in normal adenohypophysis or in any of the 10 noninvasive PAs.

Conclusion

PBK is a highly sensitive immunohistochemical marker for invasive PA, which can be used for identifying and predicting invasion. The upfront adjuvant therapy can be planned based on the invasiveness of the PA.

Keywords

PBK - invasive - pituitary adenoma - immunohistochemistry - recurrence

Publikationsverlauf

Artikel online veröffentlicht:
13. August 2025

• References

• 1 Trouillas J, Jaffrain-Rea ML, Vasiljevic A, Raverot G, Roncaroli F, Villa C. How to classify the pituitary neuroendocrine tumors (PitNET)s in 2020. Cancers (Basel) 2020; 12 (02) 514
• 2 Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993; 33 (04) 610-617 , discussion 617–618
• 3 Yang Q, Li X. Molecular network basis of invasive pituitary adenoma: a review. Front Endocrinol (Lausanne) 2019; 10: 7
• 4 Abe Y, Matsumoto S, Kito K, Ueda N. Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells. J Biol Chem 2000; 275 (28) 21525-21531
• 5 Shih MC, Chen JY, Wu YC. et al. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer. Oncogene 2012; 31 (19) 2389-2400
• 6 Park JH, Lin ML, Nishidate T, Nakamura Y, Katagiri T. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res 2006; 66 (18) 9186-9195
• 7 Brown-Clay JD, Shenoy DN, Timofeeva O, Kallakury BV, Nandi AK, Banerjee PP. PBK/TOPK enhances aggressive phenotype in prostate cancer via β-catenin-TCF/LEF-mediated matrix metalloproteinases production and invasion. Oncotarget 2015; 6 (17) 15594-15609
• 8 WHO Classification of Tumours of Endocrine Organs. Lyon, France: International Agency for Research on Cancer; 2022
• 9 DeLellis RALR, Heitz PU, Eng C. Pathology and genetics of tumours of endocrine organs [Internet]. Accessed August 3, 2025 at: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Pathology-And-Genetics-Of-Tumours-Of-Endocrine-Organs- . 2004
• 10 Louis DN, Perry A, Wesseling P. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 2021; 23 (08) 1231-1251
• 11 Scheithauer BW, Kovacs KT, Laws Jr ER, Randall RV. Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 1986; 65 (06) 733-744
• 12 Cristina C, Luque GM, Demarchi G. et al. Angiogenesis in pituitary adenomas: human studies and new mutant mouse models. Int J Endocrinol 2014; 2014: 608497
• 13 Carbia-Nagashima A, Gerez J, Perez-Castro C. et al. RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell 2007; 131 (02) 309-323
• 14 Xiao Z, Liu Q, Zhao B, Wu J, Lei T. Hypoxia induces hemorrhagic transformation in pituitary adenomas via the HIF-1α signaling pathway. Oncol Rep 2011; 26 (06) 1457-1464
• 15 Shimoda Y, Ogawa Y, Watanabe M, Tominaga T. Clinicopathological investigation of vascular endothelial growth factor and von Hippel-Lindau gene-related protein expression in immunohistochemically negative pituitary adenoma–possible involvement in tumor aggressiveness. Endocr Res 2013; 38 (04) 242-250
• 16 Gong J, Zhao Y, Abdel-Fattah R. et al. Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas. Pituitary 2008; 11 (01) 37-48
• 17 Liu W, Matsumoto Y, Okada M. et al. Matrix metalloproteinase 2 and 9 expression correlated with cavernous sinus invasion of pituitary adenomas. J Med Invest 2005; 52 (3-4): 151-158
• 18 Filippella M, Galland F, Kujas M. et al. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol (Oxf) 2006; 65 (04) 536-543
• 19 Kruthika BS, Jain R, Arivazhagan A. et al. Transcriptome profiling reveals PDZ binding kinase as a novel biomarker in peritumoral brain zone of glioblastoma. J Neurooncol 2019; 141 (02) 315-325
• 20 Joel M, Mughal AA, Grieg Z. et al. Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo. Mol Cancer 2015; 14: 121
• 21 Chatzellis E, Alexandraki KI, Androulakis II, Kaltsas G. Aggressive pituitary tumors. Neuroendocrinology 2015; 101 (02) 87-104
• 22 Huang H, Lee MH, Liu K, Dong Z, Ryoo Z, Kim MO. PBK/TOPK: an effective drug target with diverse therapeutic potential. Cancers (Basel) 2021; 13 (09) 2232